Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenbin prescription is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily investigated for the management of postoperative gastrointestinal dysmotility (PGD) in patients undergoing surgery for colorectal cancer or gynecological diseases. The formulation typically contains herbal ingredients such as *Radix Ginseng* (Shen) and *Semen Arecae* (Binlang), which are traditionally used to tonify Qi and promote gastrointestinal movement. In clinical trials, it is evaluated for its ability to restore bowel function, reduce the time to first flatus and defecation, and modulate gastrointestinal hormones such as motilin and gastrin following surgical trauma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenbin prescription.